Insulet Corporation $PODD Shares Sold by OLD National Bancorp IN

OLD National Bancorp IN cut its stake in shares of Insulet Corporation (NASDAQ:PODD) by 16.6% during the second quarter, HoldingsChannel.com reports. The firm owned 734 shares of the medical instruments supplier’s stock after selling 146 shares during the period. OLD National Bancorp IN’s holdings in Insulet were worth $231,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Nissay Asset Management Corp Japan ADV lifted its position in Insulet by 0.6% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier’s stock valued at $2,222,000 after buying an additional 48 shares in the last quarter. Mather Group LLC. increased its stake in Insulet by 4.4% during the second quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier’s stock valued at $360,000 after purchasing an additional 48 shares during the last quarter. Brooklyn Investment Group boosted its stake in Insulet by 7.0% in the first quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier’s stock valued at $209,000 after acquiring an additional 52 shares during the period. Cooper Financial Group boosted its holdings in shares of Insulet by 5.7% during the first quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier’s stock valued at $283,000 after acquiring an additional 58 shares during the period. Finally, HighTower Advisors LLC boosted its holdings in shares of Insulet by 2.1% during the first quarter. HighTower Advisors LLC now owns 2,882 shares of the medical instruments supplier’s stock valued at $757,000 after acquiring an additional 60 shares during the period.

Analysts Set New Price Targets

Several brokerages have commented on PODD. Oppenheimer boosted their price target on shares of Insulet from $324.00 to $365.00 and gave the stock an “outperform” rating in a research report on Monday, September 8th. Citigroup reiterated a “buy” rating on shares of Insulet in a report on Tuesday, July 8th. Barclays boosted their price target on Insulet from $266.00 to $300.00 and gave the company an “equal weight” rating in a research note on Thursday, August 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Insulet in a research report on Wednesday. Finally, JPMorgan Chase & Co. upped their target price on Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $346.83.

Insider Buying and Selling at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by corporate insiders.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $315.49 on Thursday. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The business has a fifty day simple moving average of $322.51 and a 200 day simple moving average of $299.51. Insulet Corporation has a one year low of $225.37 and a one year high of $353.50. The firm has a market capitalization of $22.21 billion, a price-to-earnings ratio of 95.89, a PEG ratio of 2.60 and a beta of 1.40.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. During the same period in the prior year, the company posted $0.55 earnings per share. The business’s revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts expect that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.